These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19782961)

  • 1. Screening and treating for primary cytomegalovirus infection in pregnancy: where do we stand? A decision-analytic and economic analysis.
    Cahill AG; Odibo AO; Stamilio DM; Macones GA
    Am J Obstet Gynecol; 2009 Nov; 201(5):466.e1-7. PubMed ID: 19782961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for cytomegalovirus during pregnancy.
    Adler SP; Nigro G; Pereira L
    Am J Obstet Gynecol; 2010 Jul; 203(1):e15; author reply e15-6. PubMed ID: 20227052
    [No Abstract]   [Full Text] [Related]  

  • 3. Passive immunization during pregnancy for congenital cytomegalovirus infection.
    Nigro G; Adler SP; La Torre R; Best AM;
    N Engl J Med; 2005 Sep; 353(13):1350-62. PubMed ID: 16192480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-effectiveness and cost-benefit analysis.
    Rouse DJ; Andrews WW; Goldenberg RL; Owen J
    Obstet Gynecol; 1995 Jul; 86(1):119-23. PubMed ID: 7784004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus Screening in Pregnancy: A Cost-Effectiveness and Threshold Analysis.
    Albright CM; Werner EF; Hughes BL
    Am J Perinatol; 2019 Jun; 36(7):678-687. PubMed ID: 30567003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type-specific screening for asymptomatic herpes infection in pregnancy: a decision analysis.
    Cleary KL; Paré E; Stamilio D; Macones GA
    BJOG; 2005 Jun; 112(6):731-6. PubMed ID: 15924528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of interventions to reduce vertical HIV transmission from pregnant women who have not received prenatal care.
    Mrus JM; Tsevat J
    Med Decis Making; 2004; 24(1):30-9. PubMed ID: 15005952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease.
    Akker-van Marle ME; Rijnders ME; Dommelen P; Fekkes M; Wouwe JP; Amelink-Verburg MP; Verkerk PH
    BJOG; 2005 Jun; 112(6):820-6. PubMed ID: 15924544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of routine antenatal screening for maternal herpes simplex virus-1 and -2 antibodies.
    Thung SF; Grobman WA
    Am J Obstet Gynecol; 2005 Feb; 192(2):483-8. PubMed ID: 15695991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal first-trimester cytomegalovirus screening and valaciclovir prophylaxis in pregnant persons: a cost-effectiveness analysis.
    Fisher SA; Miller ES; Yee LM; Grobman WA; Premkumar A
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100676. PubMed ID: 35714861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal-fetal cytomegalovirus infection: from diagnosis to therapy.
    Nigro G
    J Matern Fetal Neonatal Med; 2009 Feb; 22(2):169-74. PubMed ID: 19253166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the prevention and treatment of congenital cytomegalovirus infections.
    Adler SP; Nigro G; Pereira L
    Semin Perinatol; 2007 Feb; 31(1):10-8. PubMed ID: 17317422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Postma MJ; Welte R; van den Hoek JA; van Doornum GJ; Coutinho RA; Jager JC
    Ned Tijdschr Geneeskd; 1999 Mar; 143(13):677-81. PubMed ID: 10321301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A serologic strategy for detecting neonates at risk for congenital cytomegalovirus infection.
    Naessens A; Casteels A; Decatte L; Foulon W
    J Pediatr; 2005 Feb; 146(2):194-7. PubMed ID: 15689906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines on CMV congenital infection.
    Coll O; Benoist G; Ville Y; Weisman LE; Botet F; Anceschi MM; Greenough A; Gibbs RS; Carbonell-Estrany X;
    J Perinat Med; 2009; 37(5):433-45. PubMed ID: 19673682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leaning towards Cytomegalovirus serological screening in pregnancy to prevent congenital infection: a cost-effectiveness perspective.
    Seror V; Leruez-Ville M; Ӧzek A; Ville Y
    BJOG; 2022 Jan; 129(2):301-312. PubMed ID: 34651405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 2-year study on cytomegalovirus infection during pregnancy in a French hospital.
    Picone O; Vauloup-Fellous C; Cordier AG; Parent Du Châtelet I; Senat MV; Frydman R; Grangeot-Keros L
    BJOG; 2009 May; 116(6):818-23. PubMed ID: 19432571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: a cost-effectiveness analysis.
    Little SE; Caughey AB
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1274-9. PubMed ID: 16157151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of prenatal screening for spinal muscular atrophy.
    Little SE; Janakiraman V; Kaimal A; Musci T; Ecker J; Caughey AB
    Am J Obstet Gynecol; 2010 Mar; 202(3):253.e1-7. PubMed ID: 20207244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus: should we screen pregnant women for primary infection?
    Johnson JM; Anderson BL
    Am J Perinatol; 2013 Feb; 30(2):121-4. PubMed ID: 23292913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.